Delayed graft function (DGF) is a transplant complication which means a need to dialysis throughout the first week after transplantation. This study aimed to ascertain the relationship between the two immunomodulatory factors of soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble fibrinogen-like protein 2 (sFGL-2) with DGF after transplantation.
INTRODUCTION
Human kidney transplantation is the most effective treatment of chronic advanced renal failure. Although this method relieves patients of many complications of dialysis, it has some complications on its own, one of which is Delayed Graft Function (DGF) 1 accelerating 10% rate of rejection. While the traditional definition of DGF rests on dialysis requirement during the first postoperative week, it has been functionally defined as increase of serum creatinine at least 10% daily on 3 successive days during the first week post-transplantation. 2 Recent studies have proved some relationships between DGF and long term complications of transplantation 3 including decreased graft survival and increased risk of graft rejection. 4 Vascular endothelial growth factor (VEGF) is an important growth factor which is secreted by many cells and takes part in angiogenesis. 5 There are 3 main VEGF receptor subgroups which may be membranebound or soluble. 6 Soluble fms-like tyrosine kinase-1 (sFlt-1) is a splice variant of VEGF receptor-1 7 which is produced by endothelial cells, monocytes and platelets and, as a potent antagonist of VEGF, binds and sequesters VEGF. Thus, the effectiveness of VEGF would be reduced in the presence of increased levels of sFlt-1. Considering the inflammatory effects of VEGF, 8 we may assume that sFtl-1 modulates the immune responses in some pathologies. 9, 10 Soluble Fibrinogen-Like protein 2 (sFGL-2), as a soluble member of the superfamily of proteins related to fibrinogen, is a molecule holding regulatory capabilities in the immune system and thereby is mainly secreted by regulatory T (Treg) cells including CD4 + CD25 + FoxP3 + and CD8 + CD45RO low ones. 11, 12 In fact, this factor induces the apoptosis of different immune cells [13] [14] [15] [16] and in this way, it protects the tissue to be damaged 17 in different pathologies such as hepatitis C 18 and transplantation. 19, 20 Although the signaling process of sFGL-2 is still unclear, its relation to Mitogen-activated Protein Kinase (MAPK) signaling pathway 21 induces the inhibitory functions of Th17/Treg cells in different pathologies such as tumors. 22 sFlt-1 and sFGL-2 have not been addressed as effective factors on the pathologic condition of DGF so far. Changed levels of sFlt-1and sFGL-2 in DGF patients compared to those in non-DGF patients may endorse such effectiveness. If so, modulators of such factors may be able to affect DGF fate; and in this way, they may accelerate the recovery of kidney function to normal state after transplantation.
MATERIALS AND METHODS

Study Population
This retrospective study was performed on 2 groups of 58 first kidney-transplant adults with and without DGF at Baqiyatallah hospital, Tehran, during 2016. Both groups had a living donor and were matched according to age, sex, family relation to the donor, panel reactive antibody (PRA), no history of transfusion, and the rate of HLA mismatch. Having excluded any patient with hyperkalemia, urinary as well as cardiovascular disease, and any cause of renal dysfunction including surgical complications and renal vein or artery thrombosis, we confirmed the diagnosis of DGF according to each way of a) need for dialysis in the first week after transplantation, b) increasing more than or decreasing less than 10% of serum creatinine within 3 days' post-transplant. The control group was selected from the patients who underwent a transplant and did not show the mentioned DGF criteria at the end of the first week. The induction, as well as maintenance immunosuppression protocol for all recipients, was composed of therapeutic adjusted doses of calcineurin inhibitors, mycophenolate mofetil, and steroids along with the study. There was no event of cytomegalovirus (CMV) and BK infection according to standard criteria, urinary and respiratory infections, and biopsy-proven acute rejection in both DGF and control groups. The study protocol was confirmed by the local ethics committee (N. KAUMS:3537(. Written informed consent was obtained from all participants.
Measurements
A serum sample was prepared from all 116 participants as soon as DGF was diagnosed in the DGF group and at the end of the first week in the control group. Samples were kept at -20 until analysis. Once collected, the samples were sent to laboratory and serum levels of sFlt-1 and sFGL-2 were evaluated by sandwich ELISA, eBioscience USA, according to kit recommendations.
Statistics
The results were expressed as mean±SD. Kolmogorov Simonov test for Normality of the quantitative variables was assessed. The groups were compared by independent t-test and differences in proportions were tested using Chi-square and Fisher's exact test. Multiple binary logistic regression analysis was used to adjust the effect of probable confounding variables. Using ROC and Area under Curve, we tried to determine the sensitivity and specificity of sFlt-1 and sFGL-2 in the diagnosis of DGF. p<0.05 was considered statistically significant. All analyses were made by the SPSS package (version 16; Statistical Package for the Social Sciences, SPSS Inc., Chicago, Illinois, USA).
RESULTS
Basic and Clinical Characteristics of the Study Groups
Basic and clinical characteristics of the study groups are shown in Table 1 . Serum sFlt-1 and sFGL-2 levels were significantly higher in the DGF group compared to those in the control group (p<0.001).
Serum levels of sFlt-1 and sFGL-2 were significantly higher in the DGF group compared to control ones according to different demographic and clinical parameters (p<0.01) ( Table 2 ).
Evaluating the Effect of Different Variables on DGF
Using multiple logistic regression model to evaluate the effect of different confounding variables of age, gender, family relationship between donor and recipient, HLA-mismatch, percentage of PRA, type of medication, sFlt-1 and sFGL-2 on the presence or absence of DGF (as the dependent variable), we showed that DGF is affected by sFlt-1 (p=0.003) and sFGL-2 (p=0.002) levels. The model illustrated that an increase in one year of the recipient's age increases the DGF risk as much as 17% (OR=1.17), and one-unit increase of GFR decreases the risk of DGF as low as 0.944 times. The DGF risk also decreases with cyclosporine consumption (OR=0.091). It was found that each unit of increase in sFGL-2 and sFlt-1 levels significantly increases the risk of DGF 1.10 times (p=0.002) and 1.045 times (p=0.003), respectively. No significant effects of the other factors were found. However, our model showed a high power of expression (Nagelkerke R Square=0.872) and proper goodness of fit (p<0.001). GFR had a significant effect on DGF (p=0.015) in a way that any unit increase in GFR increased the risk of DGF by 6% (Table 3) .
Cut-off Points and Predictive Values
Using ROC curve and Area under Curve (AUC), we determined both sensitivity and specificity of sFlt-1 and sFGL-2 in the diagnosis of DGF. Analysis of ROC in cut-off point of 64.7 pg/mL for sFlt-1 showed 91.4% sensitivity and 74.1% specificity (AUC=0.955). Positive predictive value (PPV) and negative predictive value (NPV) of the test were 90.5% and 98.1%, respectively (Figure 1 ).
Analysis of ROC showed 98.3% sensitivity and 89.7% specificity at the cut-off point of 55.9 for sFGL-2 in the diagnosis of DGF (AUC=0.966) ( Figure 1 ). Positive predictive value (PPV) and negative predictive value (NPV) of the test were 90.5% and 98.1%, respectively. 
DISCUSSION
Our study demonstrated that sFlt-1serum levels are associated with DGF after kidney transplant. This result is in line with other studies. For example, in a relevant study, patients with DGF showed higher plasma levels of sFlt-1. 23 sFlt-1 (as a VEGF receptor) traps VEGF which is an angiogenic factor facilitating immune cell migration and adhesion; therefore, sFlt-1 may negatively regulate the inflammatory condition of graft dysfunction in organs like lungs 24 and kidneys experiencing DGF. Such result is confirmed by the observation that a recombinant version of natural sFlt-1 25, 26 as well as its adenovirus-or plasmid-mediated gene transfer 27 may inhibit angiogenesis and inflammatory indices. Similarly, antagonizing VEGFR-2 by a soluble VEGFR-2 recombinant chimeric protein ameliorates graft rejection in mice undergoing corneal transplant 28 which is well in line with a predominant anti-inflammatory mode of action of this treatment. Showing a significant positive correlation between sFlt-1 and DGF in our patients, we may consider that following DGF, sFlt-1 increases likely as a protective mechanism ameliorating the disease pathology. This might explain the reason that murine collagen-induced arthritis could be therapeutically inverted via sFlt-1. 29 This study was also designed to examine, for the first time, the possible effect of sFGL-2 on DGF. sFGL-2 is secreted from Tregs which have regulatory capabilities in some pathologic conditions. For example, previous studies have shown significantly increased serum level of sFGL-2 in allograft kidney transplant recipients with acute rejection 30, 31 perhaps due to the fact that the host tries to compensate for the injury during acute rejection process. 32, 33 Showing a significant positive correlation between sFGL-2 and DGF in our patients, we may consider that following DGF, sFGL-2 increases likely as a protective mechanism ameliorating the disease pathology.
Actually, the emergence of more sFGL-2 in splenic Tregs of transplant models indicates the involvement of such factor in inhibitory functions of Tregs 34 as well as long-term survival after transplantation. 35 Although the sFGL-2 impact is uncertain on B cells, it may protect the graft through apoptosis of such cells. 36 Our study suffered from some limitations. First, functional assays which provide further information on the immunomodulatory effect of sFlt-1, as well as sFGL-2 on DGF, were not performed. Second, we missed an extra checkpoint sampling. Further control points yield a better assessment of such factors in the prediction of DGF.
The results of our study showed an increased serum level of sFlt-1 as well as sFGL-2 associated with DGF. Considering their inhibitory roles, we may consider a protective role for both molecules among DGF. This concept may confirm the beneficial effects of sFlt-1 and sFGL-2 as diagnostic factors as well as novel therapeutics in DGF conditions after transplantation.
